BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Wirth TC, Kühnel F. Neoantigen Targeting-Dawn of a New Era in Cancer Immunotherapy? Front Immunol 2017;8:1848. [PMID: 29312332 DOI: 10.3389/fimmu.2017.01848] [Cited by in Crossref: 51] [Cited by in F6Publishing: 49] [Article Influence: 10.2] [Reference Citation Analysis]
Number Citing Articles
1 Hu LF, Lan HR, Huang D, Li XM, Jin KT. Personalized Immunotherapy in Colorectal Cancers: Where Do We Stand? Front Oncol 2021;11:769305. [PMID: 34888246 DOI: 10.3389/fonc.2021.769305] [Reference Citation Analysis]
2 Mistarz A, Komorowski MP, Graczyk MA, Gil M, Jiang A, Opyrchal M, Rokita H, Odunsi KO, Kozbor D. Recruitment of Intratumoral CD103+ Dendritic Cells by a CXCR4 Antagonist-Armed Virotherapy Enhances Antitumor Immunity. Mol Ther Oncolytics 2019;14:233-45. [PMID: 31384667 DOI: 10.1016/j.omto.2019.06.003] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
3 Zhuo M, Gorgun FM, Tyler DS, Englander EW. Transient activation of tumoral DNA damage tolerance pathway coupled with immune checkpoint blockade exerts durable tumor regression in mouse melanoma. Pigment Cell Melanoma Res 2021;34:605-17. [PMID: 33124186 DOI: 10.1111/pcmr.12943] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
4 Lu T, Wang S, Xu L, Zhou Q, Singla N, Gao J, Manna S, Pop L, Xie Z, Chen M, Luke JJ, Brugarolas J, Hannan R, Wang T. Tumor neoantigenicity assessment with CSiN score incorporates clonality and immunogenicity to predict immunotherapy outcomes. Sci Immunol 2020;5:eaaz3199. [PMID: 32086382 DOI: 10.1126/sciimmunol.aaz3199] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 7.0] [Reference Citation Analysis]
5 Rus Bakarurraini NAA, Ab Mutalib NS, Jamal R, Abu N. The Landscape of Tumor-Specific Antigens in Colorectal Cancer. Vaccines (Basel) 2020;8:E371. [PMID: 32664247 DOI: 10.3390/vaccines8030371] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
6 Xu Y, Salazar GT, Zhang N, An Z. T-cell receptor mimic (TCRm) antibody therapeutics against intracellular proteins. Antib Ther 2019;2:22-32. [PMID: 33928218 DOI: 10.1093/abt/tbz001] [Cited by in Crossref: 5] [Article Influence: 1.7] [Reference Citation Analysis]
7 Brown AJ, Snapkov I, Akbar R, Pavlović M, Miho E, Sandve GK, Greiff V. Augmenting adaptive immunity: progress and challenges in the quantitative engineering and analysis of adaptive immune receptor repertoires. Mol Syst Des Eng 2019;4:701-36. [DOI: 10.1039/c9me00071b] [Cited by in Crossref: 26] [Article Influence: 8.7] [Reference Citation Analysis]
8 Stergiou N, Urschbach M, Gabba A, Schmitt E, Kunz H, Besenius P. The Development of Vaccines from Synthetic Tumor-Associated Mucin Glycopeptides and their Glycosylation-Dependent Immune Response. Chem Rec 2021;21:3313-31. [PMID: 34812564 DOI: 10.1002/tcr.202100182] [Reference Citation Analysis]
9 Li F, Deng L, Jackson KR, Talukder AH, Katailiha AS, Bradley SD, Zou Q, Chen C, Huo C, Chiu Y, Stair M, Feng W, Bagaev A, Kotlov N, Svekolkin V, Ataullakhanov R, Miheecheva N, Frenkel F, Wang Y, Zhang M, Hawke D, Han L, Zhou S, Zhang Y, Wang Z, Decker WK, Sonnemann HM, Roszik J, Forget MA, Davies MA, Bernatchez C, Yee C, Bassett R, Hwu P, Du X, Lizee G. Neoantigen vaccination induces clinical and immunologic responses in non-small cell lung cancer patients harboring EGFR mutations. J Immunother Cancer 2021;9:e002531. [PMID: 34244308 DOI: 10.1136/jitc-2021-002531] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
10 Gerber HP, Sibener LV, Lee LJ, Gee MH. Identification of Antigenic Targets. Trends Cancer 2020;6:299-318. [PMID: 32209445 DOI: 10.1016/j.trecan.2020.01.002] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
11 Demeure MJ. The Role of Precision Medicine in the Diagnosis and Treatment of Patients with Rare Cancers. Cancer Treat Res 2019;178:81-108. [PMID: 31209842 DOI: 10.1007/978-3-030-16391-4_3] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
12 Dao T, Klatt MG, Korontsvit T, Mun SS, Guzman S, Mattar M, Zivanovic O, Kyi CK, Socci ND, O'Cearbhaill RE, Scheinberg DA. Impact of tumor heterogeneity and microenvironment in identifying neoantigens in a patient with ovarian cancer. Cancer Immunol Immunother 2021;70:1189-202. [PMID: 33123756 DOI: 10.1007/s00262-020-02764-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
13 Servín-Blanco R, Chávaro-Ortiz RM, Zamora-Alvarado R, Martínez-Cortes F, Gevorkian G, Manoutcharian K. Generation of cancer vaccine immunogens derived from major histocompatibility complex (MHC) class I molecules using variable epitope libraries. Immunol Lett 2018;204:47-54. [PMID: 30339819 DOI: 10.1016/j.imlet.2018.10.008] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
14 Fang X, Guo Z, Liang J, Wen J, Liu Y, Guan X, Li H. Neoantigens and their potential applications in tumor immunotherapy. Oncol Lett 2022;23:88. [PMID: 35126730 DOI: 10.3892/ol.2022.13208] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Mardiana S, Gill S. CAR T Cells for Acute Myeloid Leukemia: State of the Art and Future Directions. Front Oncol 2020;10:697. [PMID: 32435621 DOI: 10.3389/fonc.2020.00697] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 12.5] [Reference Citation Analysis]
16 Mak TW. From the T-cell receptor to cancer therapy: an interview with Tak W. Mak. Cell Death Differ 2021;28:5-14. [PMID: 33335286 DOI: 10.1038/s41418-020-00666-y] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
17 Wang QT, Nie Y, Sun SN, Lin T, Han RJ, Jiang J, Li Z, Li JQ, Xiao YP, Fan YY, Yuan XH, Zhang H, Zhao BB, Zeng M, Li SY, Liao HX, Zhang J, He YW. Tumor-associated antigen-based personalized dendritic cell vaccine in solid tumor patients. Cancer Immunol Immunother 2020;69:1375-87. [PMID: 32078016 DOI: 10.1007/s00262-020-02496-w] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 8.5] [Reference Citation Analysis]
18 Buckle AM, Borg NA. Integrating Experiment and Theory to Understand TCR-pMHC Dynamics. Front Immunol 2018;9:2898. [PMID: 30581442 DOI: 10.3389/fimmu.2018.02898] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.8] [Reference Citation Analysis]
19 Schabath MB, Dalvi TB, Dai HA, Crim AL, Midha A, Shire N, Gimbrone NT, Walker J, Greenawalt DM, Lawrence D, Rigas JR, Brody R, Potter D, Kumar NS, Huntsman SA, Gray JE. A Molecular Epidemiological Analysis Of Programmed Cell Death Ligand-1 (PD-L1) Protein Expression, Mutations And Survival In Non-Small Cell Lung Cancer. Cancer Manag Res 2019;11:9469-81. [PMID: 31819612 DOI: 10.2147/CMAR.S218635] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
20 Canning M, Guo G, Yu M, Myint C, Groves MW, Byrd JK, Cui Y. Heterogeneity of the Head and Neck Squamous Cell Carcinoma Immune Landscape and Its Impact on Immunotherapy. Front Cell Dev Biol 2019;7:52. [PMID: 31024913 DOI: 10.3389/fcell.2019.00052] [Cited by in Crossref: 73] [Cited by in F6Publishing: 62] [Article Influence: 24.3] [Reference Citation Analysis]
21 Shemesh CS, Hsu JC, Hosseini I, Shen BQ, Rotte A, Twomey P, Girish S, Wu B. Personalized Cancer Vaccines: Clinical Landscape, Challenges, and Opportunities. Mol Ther 2021;29:555-70. [PMID: 33038322 DOI: 10.1016/j.ymthe.2020.09.038] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 7.5] [Reference Citation Analysis]
22 Ren Y, Cherukuri Y, Wickland DP, Sarangi V, Tian S, Carter JM, Mansfield AS, Block MS, Sherman ME, Knutson KL, Lin Y, Asmann YW. HLA class-I and class-II restricted neoantigen loads predict overall survival in breast cancer. Oncoimmunology 2020;9:1744947. [PMID: 32523802 DOI: 10.1080/2162402X.2020.1744947] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
23 Zhang S, Wang H, Ding X, Xiao Y, Shao Z, You C, Gu Y, Jiang Y. Bidirectional Crosstalk between Therapeutic Cancer Vaccines and the Tumor Microenvironment: Beyond Tumor Antigens. Fundamental Research 2022. [DOI: 10.1016/j.fmre.2022.03.009] [Reference Citation Analysis]
24 da Silva JL, Dos Santos ALS, Nunes NCC, de Moraes Lino da Silva F, Ferreira CGM, de Melo AC. Cancer immunotherapy: the art of targeting the tumor immune microenvironment. Cancer Chemother Pharmacol 2019;84:227-40. [PMID: 31240384 DOI: 10.1007/s00280-019-03894-3] [Cited by in Crossref: 26] [Cited by in F6Publishing: 30] [Article Influence: 8.7] [Reference Citation Analysis]
25 Wu W, Chen Y, Huang L, Li W, Tao C, Shen H. Point mutation screening of tumor neoantigens and peptide-induced specific cytotoxic T lymphocytes using The Cancer Genome Atlas database. Oncol Lett 2020;20:123. [PMID: 32934692 DOI: 10.3892/ol.2020.11986] [Reference Citation Analysis]
26 Wing JB, Tanaka A, Sakaguchi S. Human FOXP3+ Regulatory T Cell Heterogeneity and Function in Autoimmunity and Cancer. Immunity 2019;50:302-16. [PMID: 30784578 DOI: 10.1016/j.immuni.2019.01.020] [Cited by in Crossref: 177] [Cited by in F6Publishing: 174] [Article Influence: 59.0] [Reference Citation Analysis]
27 Li Q, Ding ZY. The Ways of Isolating Neoantigen-Specific T Cells. Front Oncol 2020;10:1347. [PMID: 32850430 DOI: 10.3389/fonc.2020.01347] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
28 Santos-sierra S. Developments in anticancer vaccination: budding new adjuvants. Biological Chemistry 2020;401:435-46. [DOI: 10.1515/hsz-2019-0383] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
29 Chou C, Li MO. Tissue-Resident Lymphocytes Across Innate and Adaptive Lineages. Front Immunol 2018;9:2104. [PMID: 30298068 DOI: 10.3389/fimmu.2018.02104] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 3.8] [Reference Citation Analysis]
30 Haruki K, Kosumi K, Li P, Arima K, Väyrynen JP, Lau MC, Twombly TS, Hamada T, Glickman JN, Fujiyoshi K, Chen Y, Du C, Guo C, Väyrynen SA, Dias Costa A, Song M, Chan AT, Meyerhardt JA, Nishihara R, Fuchs CS, Liu L, Zhang X, Wu K, Giannakis M, Nowak JA, Ogino S. An integrated analysis of lymphocytic reaction, tumour molecular characteristics and patient survival in colorectal cancer. Br J Cancer 2020;122:1367-77. [PMID: 32157241 DOI: 10.1038/s41416-020-0780-3] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
31 Afonso J, Santos LL, Longatto-Filho A, Baltazar F. Competitive glucose metabolism as a target to boost bladder cancer immunotherapy. Nat Rev Urol 2020;17:77-106. [PMID: 31953517 DOI: 10.1038/s41585-019-0263-6] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 13.5] [Reference Citation Analysis]
32 Salewski I, Gladbach YS, Kuntoff S, Irmscher N, Hahn O, Junghanss C, Maletzki C. In vivo vaccination with cell line-derived whole tumor lysates: neoantigen quality, not quantity matters. J Transl Med 2020;18:402. [PMID: 33087163 DOI: 10.1186/s12967-020-02570-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
33 Londhe VY, Date V. Personalized neoantigen vaccines: a glimmer of hope for glioblastoma. Expert Rev Vaccines 2020;19:407-17. [PMID: 32238056 DOI: 10.1080/14760584.2020.1750376] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
34 Lou B, De Beuckelaer A, Boonstra E, Li D, De Geest BG, De Koker S, Mastrobattista E, Hennink WE. Modular core-shell polymeric nanoparticles mimicking viral structures for vaccination. Journal of Controlled Release 2019;293:48-62. [DOI: 10.1016/j.jconrel.2018.11.006] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 4.3] [Reference Citation Analysis]
35 Caprioli C, Nazari I, Milovanovic S, Pelicci PG. Single-Cell Technologies to Decipher the Immune Microenvironment in Myeloid Neoplasms: Perspectives and Opportunities. Front Oncol 2021;11:796477. [PMID: 35186713 DOI: 10.3389/fonc.2021.796477] [Reference Citation Analysis]
36 Koster J, Plasterk RHA. A library of Neo Open Reading Frame peptides (NOPs) as a sustainable resource of common neoantigens in up to 50% of cancer patients. Sci Rep 2019;9:6577. [PMID: 31036835 DOI: 10.1038/s41598-019-42729-2] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 4.3] [Reference Citation Analysis]
37 Chen X, Yang J, Wang L, Liu B. Personalized neoantigen vaccination with synthetic long peptides: recent advances and future perspectives. Theranostics 2020;10:6011-23. [PMID: 32483434 DOI: 10.7150/thno.38742] [Cited by in Crossref: 26] [Cited by in F6Publishing: 21] [Article Influence: 13.0] [Reference Citation Analysis]
38 Verma A, Halder A, Marathe S, Purwar R, Srivastava S. A proteogenomic approach to target neoantigens in solid tumors. Expert Rev Proteomics 2020;17:797-812. [PMID: 33491499 DOI: 10.1080/14789450.2020.1881889] [Reference Citation Analysis]
39 Besser H, Yunger S, Merhavi-Shoham E, Cohen CJ, Louzoun Y. Level of neo-epitope predecessor and mutation type determine T cell activation of MHC binding peptides. J Immunother Cancer 2019;7:135. [PMID: 31118084 DOI: 10.1186/s40425-019-0595-z] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
40 Acebes-Fernández V, Landeria-Viñuela A, Juanes-Velasco P, Hernández AP, Otazo-Perez A, Manzano-Román R, Gongora R, Fuentes M. Nanomedicine and Onco-Immunotherapy: From the Bench to Bedside to Biomarkers. Nanomaterials (Basel) 2020;10:E1274. [PMID: 32610601 DOI: 10.3390/nano10071274] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
41 Blanc E, Holtgrewe M, Dhamodaran A, Messerschmidt C, Willimsky G, Blankenstein T, Beule D. Identification and ranking of recurrent neo-epitopes in cancer. BMC Med Genomics 2019;12:171. [PMID: 31775766 DOI: 10.1186/s12920-019-0611-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
42 Beltrán Lissabet JF, Herrera Belén L, Farias JG. TTAgP 1.0: A computational tool for the specific prediction of tumor T cell antigens. Computational Biology and Chemistry 2019;83:107103. [DOI: 10.1016/j.compbiolchem.2019.107103] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
43 Jayant K, Habib N, Huang KW, Warwick J, Arasaradnam R. Recent Advances: The Imbalance of Immune Cells and Cytokines in the Pathogenesis of Hepatocellular Carcinoma. Diagnostics (Basel). 2020;10. [PMID: 32466214 DOI: 10.3390/diagnostics10050338] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
44 Rolfs Z, Solntsev SK, Shortreed MR, Frey BL, Smith LM. Global Identification of Post-Translationally Spliced Peptides with Neo-Fusion. J Proteome Res 2019;18:349-58. [PMID: 30346791 DOI: 10.1021/acs.jproteome.8b00651] [Cited by in Crossref: 9] [Cited by in F6Publishing: 16] [Article Influence: 2.3] [Reference Citation Analysis]
45 Pati S, Chowdhury A, Mukherjee S, Guin A, Mukherjee S, Sa G. Regulatory lymphocytes: the dice that resolve the tumor endgame. Appl Cancer Res 2020;40. [DOI: 10.1186/s41241-020-00091-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
46 Posner J, Barrington P, Brier T, Datta-Mannan A. Monoclonal Antibodies: Past, Present and Future. Handb Exp Pharmacol 2019;260:81-141. [PMID: 31820172 DOI: 10.1007/164_2019_323] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 6.0] [Reference Citation Analysis]
47 Chhipi-Shrestha JK, Schneider-Poetsch T, Suzuki T, Mito M, Khan K, Dohmae N, Iwasaki S, Yoshida M. Splicing modulators elicit global translational repression by condensate-prone proteins translated from introns. Cell Chem Biol 2021:S2451-9456(21)00355-X. [PMID: 34520743 DOI: 10.1016/j.chembiol.2021.07.015] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
48 Ding Z, Li Q, Zhang R, Xie L, Shu Y, Gao S, Wang P, Su X, Qin Y, Wang Y, Fang J, Zhu Z, Xia X, Wei G, Wang H, Qian H, Guo X, Gao Z, Wang Y, Wei Y, Xu Q, Xu H, Yang L. Personalized neoantigen pulsed dendritic cell vaccine for advanced lung cancer. Signal Transduct Target Ther 2021;6:26. [PMID: 33473101 DOI: 10.1038/s41392-020-00448-5] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 7.0] [Reference Citation Analysis]
49 Wessolly M, Walter RFH, Vollbrecht C, Werner R, Borchert S, Schmeller J, Mairinger E, Herold T, Streubel A, Christoph DC, Eberhardt WEE, Kollmeier J, Mairinger T, Schmid KW, Wohlschlaeger J, Hager T, Mairinger FD. Processing Escape Mechanisms Through Altered Proteasomal Cleavage of Epitopes Affect Immune Response in Pulmonary Neuroendocrine Tumors. Technol Cancer Res Treat 2018;17:153303381881841. [DOI: 10.1177/1533033818818418] [Cited by in Crossref: 4] [Article Influence: 1.0] [Reference Citation Analysis]
50 Cohen NA, Strong VE, Janjigian YY. Checkpoint blockade in esophagogastric cancer. J Surg Oncol 2018;118:77-85. [PMID: 29878357 DOI: 10.1002/jso.25116] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
51 Gómez-Aguado I, Rodríguez-Castejón J, Vicente-Pascual M, Rodríguez-Gascón A, Solinís MÁ, Del Pozo-Rodríguez A. Nanomedicines to Deliver mRNA: State of the Art and Future Perspectives. Nanomaterials (Basel) 2020;10:E364. [PMID: 32093140 DOI: 10.3390/nano10020364] [Cited by in Crossref: 33] [Cited by in F6Publishing: 31] [Article Influence: 16.5] [Reference Citation Analysis]
52 Ferreira JA, Relvas-Santos M, Peixoto A, M N Silva A, Lara Santos L. Glycoproteogenomics: Setting the Course for Next-generation Cancer Neoantigen Discovery for Cancer Vaccines. Genomics Proteomics Bioinformatics 2021:S1672-0229(21)00097-8. [PMID: 34118464 DOI: 10.1016/j.gpb.2021.03.005] [Reference Citation Analysis]
53 Xu P, Luo H, Kong Y, Lai WF, Cui L, Zhu X. Cancer neoantigen: Boosting immunotherapy. Biomed Pharmacother 2020;131:110640. [PMID: 32836075 DOI: 10.1016/j.biopha.2020.110640] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 6.5] [Reference Citation Analysis]
54 Lombardi A, Mondelli MU. Review article: immune checkpoint inhibitors and the liver, from therapeutic efficacy to side effects. Aliment Pharmacol Ther 2019;50:872-84. [PMID: 31378985 DOI: 10.1111/apt.15449] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 6.3] [Reference Citation Analysis]
55 Chen T, Hu R, Wan Y, Sun F, Wang Z, Yue J, Chen J, Han G, Wei G, Dong Z. Comprehensive mutanome analysis of Lewis lung cancer reveals immunogenic neoantigens for therapeutic vaccines. Biochem Biophys Res Commun 2020;525:607-13. [PMID: 32115148 DOI: 10.1016/j.bbrc.2020.02.132] [Reference Citation Analysis]
56 Schischlik F, Jäger R, Rosebrock F, Hug E, Schuster M, Holly R, Fuchs E, Milosevic Feenstra JD, Bogner E, Gisslinger B, Schalling M, Rumi E, Pietra D, Fischer G, Faé I, Vulliard L, Menche J, Haferlach T, Meggendorfer M, Stengel A, Bock C, Cazzola M, Gisslinger H, Kralovics R. Mutational landscape of the transcriptome offers putative targets for immunotherapy of myeloproliferative neoplasms. Blood 2019;134:199-210. [PMID: 31064751 DOI: 10.1182/blood.2019000519] [Cited by in Crossref: 24] [Cited by in F6Publishing: 28] [Article Influence: 8.0] [Reference Citation Analysis]